As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Fintel reports that on November 13, 2024, Leerink Partners downgraded their outlook for 908 Devices (NasdaqGM:MASS) from ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...

In a report released yesterday, Daina Graybosch from Leerink Partners maintained a Hold rating on Turnstone Biologics Corp. (TSBX – ...

(Bloomberg) -- Leerink Partners, the health-care advisory firm, has continued a recent recruitment drive with hires from ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb Company - ...

Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of Xencor in a ...

Stock analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for shares of Zymeworks in a ...

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...

Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced th ...

On Wednesday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $1.09 which represents a decrease of $-0.10 or -8.40% from the prior close of $1.19. The stock opened at $1.18 ...